| Entry |
|
|---|
| Name |
Linezolid (JAN/USAN/INN);
Zyvox (TN)
|
|---|
| Product |
|
|---|
| Generic |
LINEZOLID (Alembic Pharmaceuticals), LINEZOLID (Alembic Pharmaceuticals Limited), LINEZOLID (American Health Packaging), LINEZOLID (Amneal Pharmaceuticals LLC), LINEZOLID (Ascend Laboratories), LINEZOLID (AuroMedics Pharma LLC), LINEZOLID (AvPAK), LINEZOLID (CELLTRION USA), LINEZOLID (Cadila Healthcare Limited), LINEZOLID (Camber Pharmaceuticals), LINEZOLID (Fresenius Kabi Norge AS), LINEZOLID (Fresenius Kabi USA), LINEZOLID (Greenstone LLC), LINEZOLID (Greenstone LLC), LINEZOLID (Major Pharmaceuticals), LINEZOLID (Mylan Institutional LLC), LINEZOLID (Novel Laboratories), LINEZOLID (Piramal Critical Care), LINEZOLID (REMEDYREPACK), LINEZOLID (Sagent Pharmaceuticals), LINEZOLID (Sandoz), LINEZOLID (Sun Pharmaceutical Industries), LINEZOLID (Teva Pharmaceuticals USA), LINEZOLID (West-Ward Pharmaceuticals Corp.), LINEZOLID (Zydus Pharmaceuticals (USA)) |
|---|
| Formula |
C16H20FN3O4
|
|---|
| Exact mass |
337.1438
|
|---|
| Mol weight |
337.3461
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antibacterial
DG01789 Oxazolidinone antibiotic
|
|---|
| Remark |
| Therapeutic category: | 6249 |
|
|---|
| Efficacy |
Antibacterial, Protein biosynthesis inhibitor |
|---|
| Disease |
Vancomycin-Resistant Enterococcus faecium infection [DS: H00340] |
|---|
| Target |
50S ribosomal subunit |
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J01 ANTIBACTERIALS FOR SYSTEMIC USE
J01X OTHER ANTIBACTERIALS
J01XX Other antibacterials
J01XX08 Linezolid
D00947 Linezolid (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antibacterials
Antibacterials, Other
Linezolid
D00947 Linezolid (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
624 Synthetic antibacterials
6249 Others
D00947 Linezolid (JAN/USAN/INN)
Antiinfectives [br08350.html]
Antibacterials
D00947
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00947
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00947
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00947
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 24
1 C8x C 18.4100 -19.7400
2 C8y C 18.4100 -18.3400
3 C8y C 17.1500 -17.6400
4 C8x C 15.9600 -18.3400
5 C8y C 15.9600 -19.7400
6 C8x C 17.1500 -20.4400
7 N1y N 19.6000 -17.6400
8 C1x C 20.7900 -18.3400
9 C1x C 22.0500 -17.6400
10 O2x O 22.0500 -16.2400
11 C1x C 20.7900 -15.5400
12 C1x C 19.6000 -16.2400
13 X F 17.1500 -16.2400
14 N1y N 14.7000 -20.4400
15 C1x C 13.3826 -19.9663
16 C1y C 12.5634 -21.0931
17 O7x O 13.3514 -22.2462
18 C7x C 14.6895 -21.8347
19 O6a O 15.7753 -22.7458
20 C1b C 11.1300 -21.0728
21 N1b N 10.4461 -19.8484
22 C5a C 9.0310 -19.8980
23 C1a C 8.2805 -18.6975
24 O5a O 8.3810 -21.1205
BOND 26
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 2 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 7 12 1
14 3 13 1
15 5 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 17 18 1
20 14 18 1
21 18 19 2
22 16 20 1 #Up
23 20 21 1
24 21 22 1
25 22 23 1
26 22 24 2
|
|---|
|
